Table 1.
Clinical characteristics of all patients in the study cohort who underwent robot-assisted radical prostatectomy classified according to biochemical recurrence
| N | BCR | p-value* | ||
|---|---|---|---|---|
| No | Yes | |||
| N | 337 | 77 | ||
| Age, median [IQR] | 414 | 64 [59, 69] | 65 [57, 69] | 0.8 |
| PSA pre-op (ng/ml) <10 10–20 >20 |
414 |
274 (81%) 55 (16%) 8 (2.4%) |
49 (64%) 23 (30%) 5 (6.5%) |
0.002 |
| Prostate volume (cc), median [IQR] | 414 | 40 [30, 50] | 45 [40, 60] | 0.030 |
| ISUP biopsy 1 2 3 4 5 |
414 |
42 (12%) 213 (63%) 53 (16%) 21 (6.2%) 8 (2.4%) |
5 (6.5%) 30 (39%) 20 (26%) 17 (22%) 5 (6.5%) |
<0.001 |
| ISUP specimen 1 2 3 4 5 |
414 |
3 (0.9%) 185 (55%) 118 (35%) 11 (3.3%) 20 (5.9%) |
0 (0%) 17 (22%) 39 (51%) 7 (9.1%) 14 (18%) |
<0.001 |
| ISUP upgrade No Up Down |
414 |
169 (50%) 136 (40%) 32 (9.5%) |
29 (38%) 33 (43%) 15 (19%) |
0.022 |
| Pathological stage T2 T3a T3b |
414 |
189 (56%) 138 (41%) 10 (3.0%) |
20 (26%) 42 (55%) 15 (19%) |
<0.001 |
| Surgical margin extent (mm) None ≤3 >3 |
414 |
246 (73%) 66 (20%) 25 (7.4%) |
42 (55%) 23 (30%) 12 (16%) |
0.004 |
| Surgical margin ISUP None 1 2 3 4 5 |
414 |
250 (74%) 15 (4.5%) 33 (9.8%) 17 (5.0%) 21 (6.2%) 1 (0.3%) |
43 (56%) 1 (1.3%) 8 (10%) 8 (10%) 13 (17%) 4 (5.2%) |
<0.001 |
| Largest tumour diameter median [IQR] | 414 | 20 [15, 26] | 24 [20, 34] | <0.001 |
| Follow-up time (months) median [IQR] | 414 | 46 [35, 57] | 47 [35, 59] | 0.4 |
*
Wilcoxon rank sum test; Fisher's exact test; Pearson's chi-squared test
BCR – biochemical recurrence; PSA – prostate-specific antigen; ISUP – International Society of Urological Pathology